Chicago, ILLINOIS16 Active Studies

Prostate Cancer Clinical Trials in Chicago, ILLINOIS

Find 16 actively recruiting prostate cancer clinical trials in Chicago, ILLINOIS. Connect with local research sites and explore new treatment options.

16
Active Trials
13
Sponsors
3,331
Enrolling

Recruiting Prostate Cancer Studies in Chicago

RecruitingChicago, ILLINOISNCT03574571

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the comb...

738 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingChicago, ILLINOISNCT06691984

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\])....

675 participants
Amgen
View Study Details
RecruitingChicago, ILLINOISNCT05939414

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after defini...

450 participants
Novartis Pharmaceuticals
View Study Details
RecruitingChicago, ILLINOISNCT06014255

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12...

219 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details
RecruitingChicago, ILLINOISNCT05512754

Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen

The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA....

200 participants
University of Chicago
View Study Details
RecruitingChicago, ILLINOISNCT05629494

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-speci...

198 participants
Albany Medical College
View Study Details
RecruitingChicago, ILLINOISNCT03456843

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

This randomized phase II trial studies how well surgical removal of the prostate and antiandrogen therapy with or without docetaxel work in treating men with newly diagnosed prostate cancer that has s...

190 participants
Yale University
View Study Details
RecruitingChicago, ILLINOISNCT06244004

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alo...

125 participants
Northwestern University
View Study Details
RecruitingChicago, ILLINOISNCT06636682

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also le...

100 participants
Cellvax Therapeutics Inc
View Study Details
RecruitingChicago, ILLINOISNCT04038502

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant p...

100 participants
VA Office of Research and Development
View Study Details
RecruitingChicago, ILLINOISNCT06022822

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP)...

90 participants
National Cancer Institute (NCI)
View Study Details
RecruitingChicago, ILLINOISNCT05726292

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as h...

90 participants
University of Chicago
View Study Details
RecruitingChicago, ILLINOISNCT05502315

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC)....

47 participants
Rana McKay, MD
View Study Details
RecruitingChicago, ILLINOISNCT04104893

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either ...

40 participants
VA Office of Research and Development
View Study Details
RecruitingChicago, ILLINOISNCT06616155

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocki...

39 participants
University of Michigan Rogel Cancer Center
View Study Details
RecruitingChicago, ILLINOISNCT05691465

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastati...

30 participants
National Cancer Institute (NCI)
View Study Details

About Prostate Cancer Clinical Trials in Chicago

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 16 prostate cancer clinical trials recruiting participants in Chicago, ILLINOIS. These studies are seeking a combined 3,331 participants. Research is being sponsored by Memorial Sloan Kettering Cancer Center, Amgen, Novartis Pharmaceuticals and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Chicago — FAQ

Are there prostate cancer clinical trials in Chicago?

Yes, there are 16 prostate cancer clinical trials currently recruiting in Chicago, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 16 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated March 2, 2026 from ClinicalTrials.gov